Cortexyme completed the acquisition of Novosteo for $120m.

Cortexyme, a clinical-stage biopharmaceutical company, completed the acquisition of Novosteo, a developer of a drug discovery platform, for $120m. "The acquisition of Novosteo adds a highly promising set of assets and meaningfully expands the breadth of our management team. On behalf of Cortexyme’s Board, I would like to thank Chris Lowe for his leadership as interim CEO and guiding us through this acquisition," David Lamond, Cortexyme Chairman of Board of Directors.